AQST

Aquestive Therapeutics Inc

3.78

Oct 16 • 3:59 PM ET -0.28 (-6.90%)

3.88

Aftermarket • 7:59 PM ET +0.10 (2.65%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Oct 15, 7:05 AMAquestive Therapeutics announces FDA has accepted its resubmitted Anaphylm NDA and assigned a March 16, 2027 PDUFA action date.

Peers: SUPN PRGO ALKS BHC INDV AMRX TEVA VTRS LNTH HRMY

| Held by: VTI IWM VXF XPH VTWO IWN IWO IWC FSCC SURI

Scroll to Statements

Index	RUT
Market Cap	474.43M
Enterprise Value	525.03M
Income	-78.23M
Sales	54.09M
Book/sh	-0.45
Cash/sh	0.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	147
IPO	Jul 25, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	8.77
P/B	-
P/C	4.82
P/FCF	-
EV/EBITDA	-
EV/Sales	9.71
Quick Ratio	6.74
Current Ratio	7.19
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	-0.50
EPS next Q	-0.12
EPS this Y	37.75%
EPS next Y	-2.97%
EPS next 5Y	21.87%
EPS past 3/5Y	11.13% 13.92%
Sales past 3/5Y	-2.24% -0.58%
EPS Y/Y TTM	5.86%
Sales Y/Y TTM	22.56%
EPS Q/Q	-34.09%
Sales Q/Q	38.15%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-71.43% 21.03%

Insider Own	12.48%
Insider Trans	-1.05%
Inst Own	47.41%
Inst Trans	-6.59%
ROA	-69.29%
ROE	-
ROIC	-86.35%
Gross Margin	67.04%
Oper. Margin	-97.52%
Profit Margin	-144.63%
SMA20	-18.04%
SMA50	-19.83%
SMA200	-11.43%
Trades

Shs Outstand	125.51M
Shs Float	109.85M
Short Float	26.17%
Short Ratio	10.67
Short Interest	28.75M
52W High	7.55 -49.93%
52W Low	2.93 29.01%
Volatility	7.46% 5.25%
ATR (14)	0.25
RSI (14)	27.11
Beta	1.45
Rel Volume	1.95
Avg Volume	2.69M
Volume	5,253,064

Perf Week	-20.92%
Perf Month	-18.88%
Perf Quarter	-4.18%
Perf Half Y	-12.50%
Perf YTD	-41.49%
Perf Year	-46.08%
Perf 3Y	118.50%
Perf 5Y	-2.33%
Perf 10Y	-
Recom	1.00
Target Price	9.33
Prev Close	4.06
Price	3.78
Change %	-6.90%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-26	Resumed	Oppenheimer	Outperform	$8
Jun-02-25	Resumed	Oppenheimer	Outperform	$7
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$17
May-10-24	Initiated	Leerink Partners	Outperform	$8
Apr-11-24	Initiated	Piper Sandler	Overweight	$10
Mar-28-24	Initiated	Raymond James	Outperform	$7
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$7
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy	$14
Aug-20-18	Initiated	RBC Capital Mkts	Outperform	$23
Aug-20-18	Initiated	JMP Securities	Mkt Outperform	$29

Show Previous Ratings

Oct-15-26 07:00AM	Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission and PDUFA Goal Date of March 16, 2027 (GlobeNewswire) -11.93%
Sep-29-26 07:00AM	Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly (GlobeNewswire)
Sep-17-26 07:00AM	Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Sep-01-26 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-26 07:04PM	Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... (GuruFocus.com)
08:30AM	Loading…
08:30AM	Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-11-26 04:22PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:21AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 40% Downside (GuruFocus.com)
Aug-10-26 10:24AM	Aquestive Therapeutics shares jump after encouraging Anaphylm study results (InvestorsHub) +8.88%
09:20AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside (GuruFocus.com)
07:00AM	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Jul-29-26 07:00AM	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire)
Jul-07-26 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jun-23-26 03:00AM	Does US manufacturing give drugmakers a speed edge? (Pharma Voice) +6.57%
07:03PM	Loading…
May-14-26 07:03PM	Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +14.53% -11.84%
May-13-26 04:10PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 09:31AM	Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree (GlobeNewswire)
May-06-26 07:00AM	Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET (GlobeNewswire)
Mar-30-26 07:00AM	Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Mar-26-26 09:00AM	AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt (PR Newswire)
Mar-20-26 07:00AM	Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer (GlobeNewswire)
Mar-12-26 09:00AM	AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt (PR Newswire) -5.62%
Mar-09-26 04:01PM	Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 06:47PM	Aquestive Therapeutics Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... (GuruFocus.com)
08:30AM	Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-04-26 06:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics (Zacks) +6.07%
05:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:25PM	Loading…
04:25PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:20AM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Mar-03-26 07:19AM	Aquestive Therapeutics Inc (AQST) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks) +5.25%
Feb-26-26 03:48PM	Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference (MarketBeat)
Feb-25-26 07:00AM	Aquestive Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-26 07:00AM	Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET (GlobeNewswire)
Feb-23-26 04:33PM	Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay (Insider Monkey)
07:00AM	Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-20-26 07:00AM	Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-18-26 07:00AM	Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer (GlobeNewswire)
Feb-04-26 08:46AM	Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street (TipRanks)
Feb-03-26 10:45AM	Leerink sees silver lining in Aquestive CRL given defined path to approval (TipRanks)
05:50AM	Aquestive receives FDA CRL for Anaphylm allergic reaction treatment (Pharmaceutical Technology)
Feb-02-26 05:17PM	Health Care Roundup: Market Talk (The Wall Street Journal) +38.98%
01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
12:52PM	Aquestive Therapeutics Gets FDA CRL for Anaphylm, Eyes Q3 Resubmission After Human Factors Fixes (MarketBeat)
07:00AM	Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm (GlobeNewswire)
Jan-22-26 03:09AM	Jim Cramer on Aquestive Therapeutics: "I'm Not Sure If They Deserve the Benefit of the Doubt" (Insider Monkey)
Jan-14-26 09:55AM	Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-12-26 09:09PM	Lightning Round: Sony is a buy here, says Jim Cramer (CNBC TV) -10.23%
09:35AM	Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround (Zacks)
Jan-10-26 09:00AM	Morning Movers: Oklo, Vistra climb following Meta nuclear energy deals (TipRanks)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) -37.04%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
07:00AM	Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update (GlobeNewswire)
Jan-07-26 12:00PM	Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why (Zacks)
Nov-24-25 07:00AM	Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 12:09PM	Jim Cramer on Aquestive Therapeutics: "I Think It's a Very Interesting Spec" (Insider Monkey) -5.02%
Nov-11-25 08:35PM	Lightning Round: Joby Aviation is losing too much money, says Jim Cramer (CNBC TV)
Nov-06-25 02:09PM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-05-25 06:00PM	Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:37PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:44AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-25 08:14AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -6.32%
07:00AM	Aquestive Therapeutics Announces Leadership Expansion to Support Growth (GlobeNewswire)
Nov-03-25 07:00AM	Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler (GlobeNewswire)
Oct-31-25 09:40AM	Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-30-25 07:00AM	Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting (GlobeNewswire)
Oct-27-25 07:00AM	Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET (GlobeNewswire)
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks) +6.69%
Oct-10-25 08:59AM	Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? (Zacks)
Oct-08-25 07:00AM	Aquestive Therapeutics Broadens Patent Estate for Anaphylm (GlobeNewswire)
Sep-22-25 04:37AM	Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? (Zacks) -8.82%
03:42AM	Jim Cramer on Aquestive Therapeutics: "I think it's Worth Taking a Chance On" (Insider Monkey)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks) +7.11%
Sep-04-25 12:44PM	FDA Confirms Direct Review Path For Aquestive's Allergy Treatment (Benzinga) +28.10%
07:00AM	Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm (GlobeNewswire)
Aug-26-25 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 06:57AM	Aquestive signs $75m agreement for launch of Anaphylm (Pharmaceutical Technology)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:28AM	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:00AM	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Aug-11-25 07:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics (Zacks)
06:55PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:07PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:32AM	Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:25AM	Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 07:00AM	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire) +5.24%
Jul-22-25 05:20PM	USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates (Zacks) -6.15% +7.30%
07:00AM	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer (GlobeNewswire)
Jul-15-25 07:00AM	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jul-07-25 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jul-02-25 10:06PM	H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval (Insider Monkey) +8.24%
Jun-25-25 07:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit (GlobeNewswire)
Jun-24-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

CEOMr. Daniel Barber

Senior VP & CFOMr. A. Ernest Toth Jr.

Esq.Ms. Lori J. Braender BSBA

Chief Operating OfficerMs. Cassie Jung

Chief Legal Officer & Chief Compliance OfficerMr. Thomas A. Zalewski

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barber Daniel	President and CEO	Oct 15 '26	Sale	4.22	25,000	105,600	627,317	Oct 16 02:17 PM
Barber Daniel	President and CEO	Sep 15 '26	Sale	4.82	25,000	120,487	652,317	Sep 16 02:00 PM
Daniel Barber	Director	Sep 15 '26	Proposed Sale	4.88	50,000	244,000		Sep 15 04:48 PM
Korczynski Sherry	Chief Commercial Officer	Sep 09 '26	Option Exercise	2.65	8,750	23,188	244,439	Sep 11 11:07 AM
Korczynski Sherry	Chief Commercial Officer	Sep 09 '26	Sale	5.22	8,750	45,675	235,689	Sep 11 11:07 AM
Sherry M. Korczynski	Officer	Sep 09 '26	Proposed Sale	5.21	8,750	45,588		Sep 09 04:20 PM
Barber Daniel	President and CEO	Aug 17 '26	Sale	4.29	25,000	107,168	585,574	Aug 18 04:13 PM
Daniel Barber	Officer	Aug 17 '26	Proposed Sale	4.25	25,000	106,250		Aug 17 04:34 PM
Barber Daniel	President and CEO	Jul 16 '26	Sale	4.00	20,369	81,509	610,574	Jul 17 01:15 PM
Barber Daniel	President and CEO	Jul 15 '26	Sale	4.03	4,631	18,683	630,943	Jul 17 01:15 PM
Daniel Barber	Officer	Jul 15 '26	Proposed Sale	4.04	25,000	101,000		Jul 15 04:37 PM
Krop Julie	Director	Jun 23 '26	Option Exercise	0.71	25,000	17,830	25,000	Jun 24 11:11 AM
Krop Julie	Director	Jun 23 '26	Sale	5.02	25,000	125,392	0	Jun 24 11:11 AM
JULIE KROP	Director	Jun 23 '26	Proposed Sale	4.72	25,000	118,000		Jun 23 04:26 PM
Barber Daniel	President and CEO	Jun 15 '26	Sale	4.16	25,000	104,010	635,574	Jun 16 04:09 PM
Daniel Barber	Officer	Jun 15 '26	Proposed Sale	4.17	25,000	104,250		Jun 15 04:38 PM
Barber Daniel	President and CEO	May 15 '26	Sale	4.29	8,257	35,413	660,574	May 18 02:03 PM
Daniel Barber	Officer	May 15 '26	Proposed Sale	4.73	8,257	39,056		May 15 04:32 PM
Boyd Peter E.	Chief People Officer	Mar 10 '26	Sale	4.17	29,814	124,414	338,509	Mar 11 12:52 PM
Barber Daniel	President and CEO	Mar 10 '26	Sale	4.17	180,677	753,965	1,004,753	Mar 11 12:52 PM
BRAENDER LORI J	Chief Legal Officer	Mar 10 '26	Sale	4.17	40,102	167,346	442,879	Mar 11 12:52 PM
Cioffi Melina	SVP, Regulatory Affairs	Mar 10 '26	Sale	4.17	25,311	105,623	274,867	Mar 11 12:52 PM
TOTH A ERNEST JR	Chief Financial Officer	Mar 10 '26	Sale	4.17	58,254	243,094	376,112	Mar 11 12:51 PM
Korczynski Sherry	Chief Commercial Officer	Mar 10 '26	Sale	4.17	15,741	65,687	241,117	Mar 11 12:51 PM
Jung Cassie	Chief Operating Officer	Mar 10 '26	Sale	4.17	45,791	191,086	274,980	Mar 11 12:50 PM
Carl N. Kraus	Affiliate	Nov 17 '25	Proposed Sale	5.39	53,100	286,209		Nov 17 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AQST

Aquestive Therapeutics Inc

Upgrade your Finviz experience